natgillin/translations-raw huggingface dataset:
Very rare side effects that may occur (in less than 1 in 10,000 people) are: - low white blood cells: low blood platelets, which may result in bruising or easy bleeding
Zelo redki neželeni učinki (ki se pojavijo pri manj kot 1 osebi od 10.000) so:
the CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Cardoreg 4 mg prolonged release tablets and associated names (see Annex I).
je CHMP za Cardoreg 4 mg tablete s podaljšanim sproščanjem in z njim povezana imena (glejte Dodatek I) priporočil odobritev dovoljenj za promet z zdravilom, za katere so Povzetki glavnih značilnosti zdravila, označevanje in Navodila za uporabo opredeljeni v Dodatku III.
PACKAGE LEAFLET: INFORMATION FOR THE USER Cardoreg 4 mg prolonged release tablets and associated names [See Annex I] (Doxazosin)
NAVODILO ZA UPORABO Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena [glejte Dodatek I] (doksazosin)
Radioactivity was found to cross the placenta following oral administration of labelled doxazosin to pregnant rats.
Ugotovili so, da po peroralni uporabi označenega doksazosina pri brejih podganah, radioaktivnost prehaja v placento.
Uncommon: epistaxis, broncho spasms, cough, pharyngitis Rare: oedema of larynx
Občasni: epistaksa, bronhospazmi, kašelj, faringitis Redki: edem grla
One prolonged-release tablet contains 4 mg doxazosin (as mesilate).
Ena tableta s podaljšanim sproščanjem vsebuje 4,85 mg doksazosinijevega mesilata, kar ustreza 4 mg doksazosina.
Pharmacotherapeutic group: Alpha-adrenoceptor antagonists, ATC code: C02CA04
Oznaka ATC: C02CA04.
Patients treated with immediate release doxazosin tablets against hypertension can be transferred to Cardoreg 4 mg prolonged release tablets and associated names and the dose titrated upwards as needed, while maintaining effect and tolerability.
Bolniki, ki jemljejo tablete doksazosina s takojšnjim sproščanjem, lahko preidejo na zdravilo Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena.
3 HOW TO TAKE CARDOREG 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES
3 KAKO JEMATI ZDRAVILO CARDOREG 4 MG TABLETE S PODALJŠANIM SPROŠČANJEM IN POVEZANA IMENA
1 WHAT CARDOREG 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES IS AND WHAT IT IS USED FOR
1 KAJ JE ZDRAVILO CARDOREG 4 MG TABLETE S PODALJŠANIM SPROŠČANJEM IN POVEZANA IMENA IN ZA KAJ GA UPORABLJAMO
Do not take Cardoreg 4 mg prolonged release tablets and associated names
Ne jemljite zdravila Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena:
Patients with hepatic impairment: Cardoreg 4 mg prolonged release tablets and associated names should be given with particular caution to patients with evidence of impaired liver function.
Bolniki z jetrno okvaro: Bolnikom z jetrno okvaro je treba zdravilo Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena dajati posebno previdno.
Take special care with Cardoreg 4 mg prolonged release tablets and associated names
Bodite posebno pozorni pri jemanju zdravila Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena:
Always take Cardoreg 4 mg prolonged release tablets and associated names exactly as your doctor has told you.
Pri jemanju zdravila Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena natančno upoštevajte zdravnikova navodila.
Cardoreg 4 mg prolonged release tablets and associated names should be administered with caution in patients with signs of mild to moderate hepatic impairment (see section 5.2).
Pri bolnikih z manjšo do zmerno jetrno okvaro je treba zdravilo Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena odmerjati previdno (glejte poglavje 5.2).
Hepatobiliary disorders: Rare: icterus, increased liver values
Bolezni jeter, žolčnika in žolčevodov: Redki: ikterus, zvišanepovečane vrednosti jetrnih encimov
2 BEFORE YOU TAKE CARDOREG 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES
2 KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO CARDOREG 4 MG TABLETE S PODALJŠANIM SPROŠČANJEM IN POVEZANA IMENA
5 HOW TO STORE CARDOREG 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES
5 SHRANJEVANJE ZDRAVILA CARDOREG 4 MG TABLETE S PODALJŠANIM SPROŠČANJEM IN POVEZANA IMENA
Cardoreg 4 mg prolonged release tablets and associated names can cause drowsiness.
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena lahko povzroči dremavost.
Cardoreg 4 mg prolonged release tablets and associated names
Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena [glejte Dodatek I] doksazosin
Cardoreg 4 mg prolonged release tablets and associated names may be used in benign prostatic hyperplasia (BPH) patients who are either hypertensive or normotensive, as the blood pressure changes in normotensive patients are clinically insignificant.
Spremembe krvnega tlaka pri normotenzivnih bolnikih so klinično nepomembne, zato se lahko zdravilo Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena uporablja pri hipertenzivnih in tudi pri normotenzivnih bolnikih z benigno prostatično hiperplazijo prostate (BPHbenign prostatic hyperplasia).
What Cardoreg 4 mg prolonged release tablets and associated names is and what it is used for 2.
Kaj je zdravilo Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena in za kaj ga uporabljamo
Taking Cardoreg 4 mg prolonged release tablets and associated names with food and drink Cardoreg 4 mg prolonged release tablets and associated names can be taken with or after food.
Jemanje zdravila Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena skupaj s hrano in pijačo
How to take Cardoreg 4 mg prolonged release tablets and associated names 4.
Kako jemati zdravilo Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena Možni neželeni učinki
Metabolism and nutrition disorders: Uncommon: thirst, hypokalaemia, gout Rare: hypoglycaemia Very rare: increase in serum urea.
Redki: hipoglikemija Zelo redki: zvišanepovečanje vrednosti uree v serumu
Alternatively, breast-feeding must be stopped, if treatment with Cardoreg 4 mg prolonged release tablets and associated names is unavoidable.
Če je zdravljenje z zdravilom Cardoreg 4 mg tablete s podaljšanim sproščanjem in povezana imena neizogibno, je treba dojenje prekiniti.
This overview was last updated in March 2018.
Ta pregled je bil nazadnje posodobljen marca 2018.
EMA/CVMP/92087/2007 EMEA/V/C/000072
EMEA/CVMP/92087/2007 EMEA/V/C/000072
Further information on SevoFlo can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Nadaljnje informacije o zdravilu SevoFlo so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Together, these combined actions result in loss of consciousness.
Združena učinka povzročita izgubo zavesti.
The European Medicine's Agency decided that SevoFlo's benefits are greater that its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila SevoFlo večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
SevoFlo must not be given to animals with a genetic susceptibility to malignant hyperthermia.
Zdravilo SevoFlo se ne sme dajati živalim z gensko občutljivostjo na maligno hipertermijo.
Other information about SevoFlo
Druge informacije o zdravilu SevoFlo
Pregnant and breast-feeding women must not come into contact with the product and they should also avoid operating rooms and animal recovery areas where the product is being used or has recently been used.
Nosečnice in doječe matere ne smejo priti v stik z zdravilom, zato se morajo izogibati operacijskim sobam in prostorom za prebujanje živali, v katerih se zdravilo uporablja oziroma je bilo uporabljeno pred nedavnim.
What benefits of SevoFlo have been shown in studies?
Kakšne koristi je zdravilo SevoFlo izkazalo v študijah?
Why is SevoFlo authorised in the EU?
Zakaj je zdravilo SevoFlo odobreno v EU?
SevoFlo is a general anaesthetic for dogs and cats.
Zdravilo SevoFlo je splošni anestetik za pse in mačke.
Sevoflurane mimics the action of GABA, a substance that naturally reduces brain activity, and blocks the action of glutamate, which stimulates the activity of the brain.
Sevofluran posnema delovanje snovi GABA, ki naravno zavira možgansko dejavnost, in zmanjšuje delovanje glutamata, ki spodbuja delovanje možganov.
The dog or cat breathes in the gas mixture, which causes it to become unconscious.
Pes ali mačka vdihava to plinsko mešanico, kar povzroči izgubo zavesti.
What are the risks associated with SevoFlo?
Kakšna tveganja so povezana z zdravilom SevoFlo?
In addition, SevoFlo has been commonly used off-label (use that is not officially authorised) as an anaesthetic for cats for more than 10 years and therefore its use in cats is considered to be ‘well-established'.
Poleg tega se zdravilo Sevoflo kot anestetik za mačke nenamensko uporablja (brez uradnega dovoljenja) več kot 10 let, zato je njegova uporaba pri mačkah dobro uveljavljena.
The effectiveness of SevoFlo was comparable to isoflurane.
Učinkovitost zdravila SevoFlo je bila primerljiva z izofluranom.
SevoFlo is given using specialised anaesthetic equipment, usually in a carefully controlled gas mixture including oxygen.
Zdravilo SevoFlo se daje s pomočjo specializirane opreme za anestezijo, običajno v obliki natančno regulirane plinske mešanice, v kateri je tudi kisik.
An overview of SevoFlo and why it is authorised in the EU
Pregled zdravila SevoFlo in zakaj je odobreno v EU
This is a rare life-threatening condition usually triggered by exposure to certain general anaesthetics that is associated with muscle spasm and very high body temperatures.
To je redko, življenjsko nevarno stanje, ki ga lahko povzroči izpostavljenost nekaterim splošnim anestetikom ter je povezano z mišičnimi krči in zelo visoko telesno temperaturo.
When a dog or cat is given a mixture of oxygen and sevoflurane to breathe, the sevoflurane is inhaled into its lungs and is carried by the blood into the brain.
Ko pes ali mačka vdihne mešanico kisika in sevoflurana, ta preide v pljuča in se po krvi prenese v možgane.
If a person accidentally inhales sevoflurane vapour, this may cause symptoms such as shivering, nausea, headache, low blood pressure, decreased heart rate and even reduced breathing.
Če oseba nenamerno vdihava hlape sevoflurana, lahko to povzroči simptome, kot so tresavica, siljenje na bruhanje, glavobol, nizek krvni tlak, zmanjšan srčni utrip in celo upočasnjeno dihanje.
Care must therefore be taken when handling SevoFlo: any spillage must be removed immediately, the vapour must not be inhaled, and any contact with the product by mouth must be avoided.
Pri ravnanju z zdravilom SevoFlo je zato potrebna posebna pozornost: morebitno razlito zdravilo je treba takoj odstraniti, hlapi se ne smejo vdihavati, prav tako pa se je treba izogibati vsakršnemu peroralnemu stiku z zdravilom.
What is SevoFlo and what is it used for?
Kaj je zdravilo SevoFlo in za kaj se uporablja?
The most common side effects with SevoFlo, which may affect more than 1 in 10 animals, are low blood pressure, rapid breathing, muscle tenseness, excitation, a temporary inability to breathe, small muscle twitches and vomiting.
Najpogostejši neželeni učinki pri uporabi zdravila SevoFlo, ki lahko prizadenejo več kot 1 žival od 10, so nizek krvni tlak, hitro dihanje, napetost v mišicah, razdraženost, začasna nezmožnost dihanja, majhne kontrakcije mišic in bruhanje.
In case of accidental contact with the skin or eyes, or for more information, the package leaflet should be consulted.
Če pride do nenamernega stika s kožo ali očmi ali če želite več informacij, si preberite navodilo za uporabo.
Studies in dogs found that SevoFlo was as effective at starting and maintaining anaesthesia as other anaesthetic agents, such as isoflurane (another anaesthetic gas), thiopental, propofol, and ketamine plus diazepam.
Študije pri psih so pokazale, da je zdravilo SevoFlo pri povzročitvi in vzdrževanju anestezije enako učinkovito kot nekateri drugi anestetiki, npr. izofluran (drug plin za anestezijo), tiopental, propofol in ketamin z diazepamom.
SevoFlo received a marketing authorisation valid throughout the EU for SevoFlo on 11 December
Zdravilo SevoFlo je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 11. decembra 2002.
For more information about using SevoFlo, see the package leaflet or contact your veterinarian or pharmacist.
Za več informacij glede uporabe zdravila SevoFlo glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
It contains the active substance sevoflurane, a chemical which is a liquid at room temperature, but when heated becomes a gas (vaporises).
Zdravilo vsebuje učinkovino sevofluran, tj. kemično snov, ki je pri sobni temperaturi tekoča, pri segrevanju pa se uplini (upari).
Safety information has been included in the summary of product characteristics and the package leaflet for SevoFlo, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
V povzetek glavnih značilnosti zdravila SevoFlo in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
SevoFlo is used to bring about and maintain general anaesthesia (loss of consciousness).
Uporablja se za povzročitev in vzdrževanje splošne anestezije (izgube zavesti).
For the full list of side effects of SevoFlo, and for the full list of restrictions, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila SevoFlo, in seznam omejitev glejte navodilo za uporabo.
SevoFlo produced a relatively rapid and smooth start of anaesthesia in dogs, followed by a good recovery.
Zdravilo SevoFlo je dokaj hitro in brez težav uvedlo anestezijo pri psih, temu pa je sledilo uspešno prebujanje.
For cats, a review of published scientific literature showed that SevoFlo is effective for anaesthesia and that it is compatible with a range of sedative and pain-relieving medicines used in anaesthesia.
Pri mačkah je pregled objavljene znanstvene literature pokazal, da je zdravilo SevoFlo učinkovito kot anestetik ter da se lahko med anestezijo uporablja v kombinaciji z vrsto drugih sedativov in zdravil za lajšanje bolečine.
Studies showed that sevoflurane could be used safely with several other medicines commonly used in dogs before or during operations, for maintenance of anaesthesia.
Študije so pokazale, da se lahko sevofluran za vzdrževanje anestezije varno uporablja skupaj s številnimi drugimi zdravili, ki se običajno uporabljajo pri psih pred ali med kirurškim posegom.
How does SevoFlo work?
Kako zdravilo SevoFlo deluje?
How is SevoFlo used?
Kako se zdravilo SevoFlo uporablja?
Animal studies are insufficient.
Študij na živalih ni dovolj.
Austria, Belgium, Cyprus, Czech Republic, Estonia, Germany, Greece, Finland, Hungary, Iceland, Ireland, Luxembourg, The Netherlands, Norway, Slovakia, Slovenia, Spain, Sweden
Avstrija, Belgija, Ciper, Češka, Estonija, Nemčija, Grčija, Finska, Madžarska, Islandija, Irska, Luksemburg, Nizozemska, Norveška, Slovaška, Slovenija, Španija, Švedska
France, Portugal
Francija, Portugalska
It has no agonist activity.
Agonističnega delovanja nima.
Sugar in your urine.
• Sladkor v urinu.
Concomitant intake of food increases the absorption by approximately 15%.
Sočasno uživanje hrane poveča absorpcijo za približno 15 %.
you have ever had allergy or asthma.
- če ste kdaj imeli alergijo ali astmo.
If this happens to you, do not drive or use any tools or machines.
Če se vam to zgodi, ne vozite in ne upravljajte vozil ali strojev.
Medicines to treat cancer.
• Zdravila za zdravljenje raka.
A similar effect has also been reported with AIIRAs.
O podobnem učinku so poročali pri ARAII.
It is used for treating high blood pressure (hypertension) in adult patients.
Uporablja se za zdravljenje visokega krvnega tlaka (hipertenzije) pri odraslih bolnikih.
This causes moderate to severe pain in the stomach.
To povzroči zmerne do hude bolečine v trebuhu.
This medicinal product is authorised in the Member States of the EEA under the following names:
To zdravilo je odobreno v državah članicah EGP pod naslednjimi imeni: Ime zdravila
Detailed information on this medicinal product is available on the website of {name of MS/Agency}
Podrobne informacije o zdravilu so objavljene na spletni strani {ime DČ/agencije}
Taking Atacand Plus with food and drink (in particular alcohol)
Jemanje zdravila Atacand Plus skupaj s hrano in pijačo (še zlasti z alkoholom)
Approximately 70% of an oral dose is eliminated in the urine within 48 hours.
Približno 70 % peroralnega odmerka se izloči v urinu v 48 urah.
Labelling
OZNAČEVANJE
Penicillin (an antibiotic).
• Penicilin (antibiotik).
MINIMUM PARTICULARS TO APPEAR ON BLISTERS Non-Perforated calendar foil (7, 14, 28, 56 and 98 tablets)
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU Neperforiran koledarski trak (7, 14, 28, 56 in 98 tablet)
Atacand Plus is indicated for the:
Zdravilo Atacand Plus je indicirano za:
you are allergic to sulphonamide medicines.
- če ste alergični na sulfonamidna zdravila.
Pituitary hormone (ACTH).
• Hipofizni hormon (ACTH).
The frequencies used in the tables throughout section 4.8 are: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare
Pogostnosti, uporabljane v preglednicah v celotnem poglavju 4.8, so: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
Available interaction studies indicate no effect on CYP2C9 and CYP3A4.
Študije medsebojnega delovanja, ki so na voljo, ne kažejo vpliva na CYP2C9 in CYP3A4.
If a photosensitivity reaction occurs, it is recommended to stop treatment.
Če se pojavi fotosenzibilnostna reakcija, je zdravljenje priporočljivo končati.
Dose adjustment of antidiabetic medicinal products, including insulin, may be required.
Potrebna je lahko prilagoditev odmerka antidiabetičnih zdravil, vključno z insulinom.
Most of the antihypertensive effect is usually attained within 4 weeks of initiation of treatment.
Večina antihipertenzivnega učinka je po navadi dosežena v 4 tednih po začetku zdravljenja.
The safety and efficacy of Atacand Plus in children aged between birth and 18 years have not been established.
Varnost in učinkovitost zdravila Atacand Plus pri otrocih od rojstva do 18. leta starosti nista ugotovljeni.
Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded.
Epidemiološki izsledki o tveganju teratogenih učinkov po izpostavljenosti zaviralcem ACE v prvem trimesečju nosečnosti niso dokončni, toda majhnega povečanja tveganja ni mogoče izključiti.
you have ever had gout.
- če ste kdaj imeli protin.
There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester.
Izkušenj s hidroklorotiazidom med nosečnostjo je malo, še zlasti v prvem trimesečju.
Barbiturates (a type of sedative also used to treat epilepsy).
• Barbiturate (vrsto pomirjeval, ki se uporabljajo tudi za zdravljenje epilepsije).
Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.
Hidroklorotiazida ne smemo uporabljati za zdravljenje esencialne hipertenzije pri nosečnicah, razen v redkih primerih, ko ne moremo uporabiti nobenega drugega zdravljenja.
Medicines for diabetes (tablets or insulin).
• Zdravila za sladkorno bolezen (tablete ali insulin).
With continuous treatment, most of the reduction in blood pressure is attained within four weeks and is sustained during long-term treatment.
Med stalnim zdravljenjem je večina znižanja krvnega tlaka dosežena v štirih tednih in se med dolgotrajnim zdravljenjem ohrani.
The recommended dose of Atacand Plus is one tablet once daily.
Priporočeni odmerek zdravila Atacand Plus je ena tableta enkrat na dan.
severe itching of the skin (with raised lumps).
• močno srbenje kože (z dvignjenimi kožnimi spremembami).
Large clinical studies have shown that long-term treatment with hydrochlorothiazide reduces the risk for cardiovascular morbidity and mortality.
Velike klinične študije so pokazale, da dolgotrajno zdravljenje s hidroklorotiazidom zmanjša tveganje kardiovaskularne umrljivosti in obolevnosti.
The apparent volume of distribution is approximately 0.8 l/kg.
Navidezni volumen porazdelitve je približno 0,8 l/kg.
It also has a role in the pathogenesis of organ hypertrophy and end organ damage.
Vlogo ima tudi pri patogenezi hipertrofije in okvare končnih organov.
Atacand Plus may cause a reduction in number of white blood cells.
Zdravilo Atacand Plus lahko povzroči zmanjšanje števila belih krvnih celic.
Therefore do not stop taking Atacand Plus without first talking to your doctor.
Zato ne nehajte jemati zdravila Atacand Plus, ne da bi se prej posvetovali s svojim zdravnikom.
Acetylsalicylic acid (if you are taking more than 3 g each day) (medicine to relieve pain and inflammation).
• Acetilsalicilno kislino (če jo jemljete več kot 3 g na dan) (zdravilo za lajšanje bolečin in ublažitev vnetja).
If you have been told by doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se z njim posvetujte, preden vzamete to zdravilo.
Cyclosporine, a medicine used for organ transplant to avoid organ rejection.
• Ciklosporin, zdravilo, ki se uporablja za preprečevanje zavrnitve po presaditvi organa.
There was no evidence that either compound is carcinogenic.
Ni znakov, da bi bila ena ali druga spojina kancerogena.
you have a disease of the adrenal gland called Conn's syndrome (also called primary hyperaldosteronism).
- če imate bolezen nadledvičnih žlez, imenovano Connov sindrom (imenujemo jo tudi primarni hiperaldosteronizem).
These changes were considered to be caused by the pharmacological action of candesartan and to be of little clinical relevance.
Te spremembe so ocenili za posledice farmakološkega delovanja kandesartana in za klinično malo pomembne.
If you are not sure if this applies to you, please ask your doctor.
Če niste prepričani, ali to velja za vas, se posvetujte z zdravnikom.
Your doctor may occasionally do blood tests to check whether Atacand Plus has had any effect on your blood (agranulocytosis).
Zdravnik vas bo morda občasno opravil preiskavo krvi, da bo preveril, ali vam zdravilo Atacand Plus kaj vpliva na kri (agranulocitoza).
Serum electrolyte and acid balance should be checked and corrected, if needed.
Kontrolirati je treba elektrolite v serumu in acido-bazno ravnovesje ter jih korigirati, če je treba.
Important information about some of the ingredients of Atacand Plus Atacand Plus contains lactose which is a type of sugar.
Pomembne informacije o nekaterih sestavinah zdravila Atacand Plus Zdravilo Atacand Plus vsebujejo laktozo, ki je vrsta sladkorja.
Candesartan does not influence ACE or other enzyme systems usually associated with the use of ACE inhibitors.
Kandesartan ne vpliva na ACE ali druge encimske sisteme, po navadi povezane z uporabo zaviralcev ACE.
Elderly population No dose adjustment is necessary in elderly patients.
Starejša populacija Starejšim bolnikom odmerka ni treba prilagoditi.
High temperature (fever).
• Zvišana telesna temperatura (vročina).
Following an oral dose of 14C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces as candesartan and 10% as the inactive metabolite.
Po peroralnem odmerku s 14C-označenega cileksetilkandesartanata se približno 26 % odmerka izloči v urinu kot kandesartan in 7 % kot neaktivni presnovek, približno 56 % odmerka pa se pojavi v blatu kot kandesartan in 10 % kot neaktivni presnovek.